Rimiducid

Overview

Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function. When administered via chemically-inducible dimerization (CID) technologies, rimiducid binds to switch proteins and dimerizes them, triggering downstream signaling cascade. The combination use of rimiducid with immunotherapies for enhanced therapeutic effectiveness is currently under investigation.

Indication

Investigated for use/treatment in bone marrow transplant and graft versus host disease.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)	2025/05/22	NCT06984341	Phase 1	Not yet recruiting	Genentech, Inc.
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)	2024/04/10	NCT06358430	Phase 1	Recruiting	M.D. Anderson Cancer Center
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)	2023/10/04	NCT06066424	Phase 1	Recruiting	M.D. Anderson Cancer Center
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies	2023/08/28	NCT06014762	Phase 1	Recruiting	Poseida Therapeutics, Inc.
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors	2022/02/14	NCT05239143	Phase 1	Active, not recruiting	Poseida Therapeutics, Inc.
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma	2021/07/14	NCT04960579	Phase 1	Recruiting	Poseida Therapeutics, Inc.
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)	2020/01/31	NCT04249947	Phase 1	Terminated	Poseida Therapeutics, Inc.
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma	2019/05/22	NCT03958656	Phase 1	Completed	National Cancer Institute (NCI)
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant	2019/01/16	NCT03807063	Phase 1	Withdrawn	Fred Hutchinson Cancer Center
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101	2018/11/14	NCT03741127	Phase 1	Active, not recruiting	Poseida Therapeutics, Inc.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Phase 1 Trial Shows Promise for PSCA-Targeted BPX-601 CAR T-Cell Therapy in Pancreatic and Prostate Cancers

6 months ago

A phase 1 clinical trial evaluated BPX-601, a novel PSCA-targeted CAR T-cell therapy with rimiducid activation, in patients with metastatic pancreatic and prostate cancers. The study demonstrated manageable safety profile and preliminary clinical activity, though it was terminated early following dose-limiting toxicities. The innovative approach of pharmacological activation using rimiducid showed potential for enhancing CAR T-cell therapy in solid tumors.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access